Updated report from NDF research out today
http://www.ndfresearch.com/uploads/...2_15_suda_update_report_from_ndf_research.pdf
If SUDA is so good, how come the market capitalisation of the company is only A$17.1m/US$13.4m?
We think the current low market capitalisation of SUDA mostly reflects the fact that it has only struck its landmark partnering deals in 2016 and 2017, after around three years of work on its drug reformulation technology. We think that with subsequent deals the stock can significantly re-rate, particularly as the company does more work on marketing the story to the investment community
Updated report from NDF research out today...
-
- There are more pages in this discussion • 47 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.010(5.41%) |
Mkt cap ! $205.1M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 20.0¢ | 18.5¢ | $867.7K | 4.443M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 650036 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 181193 | 6 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| ALA (ASX) Chart |